Fojann Intelligence (Shanghai) Pharmaceutical Co., Ltd

语言/Language

With early screening for IBD, the inflammation is usually confined to one part of the intestine or mild. Early detection of inflammatory bowel disease (IBD) often reveals localized or mild inflammation. Prompt treatment with medications can effectively control inflammation, prevent its spread to adjacent tissues, slow disease progression, and reduce cancer risks. Early intervention also enhances mucosal repair, alleviates symptoms, and lowers relapse frequency/severity. Studies confirm that standardized early treatment significantly decreases relapse rates and promotes long-term disease stability. IBD strongly correlates with colon cancer: Chronic intestinal inflammation stimulates mucosal cells, triggering excessive production of inflammatory mediators (e.g., TNF-α, IL-6). These disrupt cellular metabolism, increase genetic mutation risks, and ultimately drive abnormal cell proliferation and carcinogenesis.

Test items: 01

Bacterial marker:Assess disease risk, such as specific bacterial species associated with Crohn's disease and their abundance.; 02

Inflammatory index:Understanding the extent of intestinal inflammation by detecting metabolites or bacterial products associated with the inflammatory response.; 03

Intestinal flora structure:To analyze the composition and diversity of the overall intestinal flora and evaluate the status of intestinal microecological balance.

Health implications: 01

Early detection of IBD:Patients with IBD are identified in the early stages of the disease for timely intervention and treatment.; 02

Directed personalized therapy:According to the test results, individual treatment plan can be developed for patients to improve the treatment effect.; 03

Monitor disease progression:Regular testing can track disease progression and treatment outcomes in patients with IBD and adjust treatment strategies.

01

Online booking test service
02

A stool sample is collected and mailed to the laboratory
03

Specialized laboratories perform microbiome analysis
04

Obtain detailed IBD non-invasive early screening test report

Data presentation: By analyzing specific bacterial biomarkers — such as the abundance of inflammation-linked pathogenic bacteria or probiotics — we reveal the balance of your gut microbiome. For instance, abnormal increases or decreases in certain bacteria may signal potential inflammatory risks. The report details levels of multiple inflammation-related indicators, which serve as direct evidence of systemic inflammatory responses. Elevated inflammatory factors, for example, may indicate active intestinal inflammation, a hallmark of IBD patients.

Conclusion interpretation: Your test results enable a personalized assessment of IBD risk. We highlight which biomarkers fall within normal ranges and which show deviations, explaining their implications for gut health. Any markers exceeding normal thresholds or suggesting potential risks are flagged and thoroughly interpreted. We clarify possible triggers for these abnormalities and their role in disease progression, empowering you to understand their significance.

Proposed scheme: Tailored dietary recommendations — such as increasing dietary fiber intake, adjusting carbohydrate types, and avoiding pro-inflammatory foods — are provided to optimize your gut microbiome environment. Beyond diet, lifestyle factors like exercise, sleep hygiene, and stress management are addressed. For high-risk individuals, we propose an ongoing health monitoring plan, including regular follow-ups and specialized screenings, to enable early detection and intervention.

When asymptomatic IBD non-invasive early screening test found intestinal microbial abnormalities, further examination confirmed early IBD, timely treatment, can avoid the deterioration of the disease.

2025-02-06

When Mr. Zhang was asymptomatic, he was found to have abnormal intestinal microorganisms through non-invasive early screening of IBD. After further examination, he was diagnosed with early IBD and received timely treatment to avoid deterioration of h

2025-02-06

Understanding Gut Health

IBD Non-invasive Early Screening Tests for Your Health Protection

Booking

Scan the QR code to make an appointment

Q

How long will it take to get the results?

A

After collection, samples are shipped back via SF Express. Upon receipt, the lab initiates immediate processing, with results available within 5-10 business days. Reports can be accessed and saved under your account in the designated mini-program section linked to your sample.
Q

Is the data confidential?

A

Access to the entire workflow (collection, analysis, storage) is restricted to authorized personnel. Personally identifiable information (PII, e.g., name, contact) is anonymized and stored separately from test results, ensuring irreversible delinking of data from individual identities.